Severity and Functional Ability Scale for Amyotrophic Lateral Sclerosis patients:
preliminary results
DOI:
https://doi.org/10.34024/rnc.2008.v16.8632Keywords:
Amyotrophic Lateral Sclerosis, Scales, Neuromuscular DiseasesAbstract
Introduction. Amyotrophic lateral sclerosis (ALS) is a progressive and fatal illness that affects the neurons of the pyramidal tracts and the anterior horn of the spinal cord. Many evaluations methods have been proposed in order to supply better follow-up information of patients as well as improved management of secondary complications. We present, in this study, a new instrument for clinical and rehabilitation follow-up of patients with ALS. Method. We evaluated 96 consecutive patients with diagnosis of ALS, in the University Hospital Antonio Pedro and in the Institute of Neurology Deolindo Couto through the Severity and Functional Ability Scale. Results. This preliminary data allowed us to delineate a 5 domain scale that measure 1) muscle strength myotome specific, 2) functional abilities, 3) swallowing function, and 4) breathing, and 5) disease stage severity. Clinical features and functional manifestations of ALS patients were heterogeneous regarding to the most frequent clinical complications and independence levels. Conclusion. These preliminary results suggest that our 5 domain scale is simple, applicable, not time consuming of, as well as easily reproducible regarding clinical course and prognosis of patients with ALS. Our pilot study grants the next step of our research that includes accuracy, internal validity, reliability, factorial analysis and other needed formal methodological and statistical procedures.
Downloads
References
Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model of survival prediction. Brain 1995;118:707-19.
Rosenfeld J, Jackson CE. Quantitative assessment and outcome measures in neuromuscular disease. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE (eds.) Neuromuscular Disorders in Clinical Practice. Boston: Butterworth Heinemann, 2002, 1416p.
Guccione AA. Physical therapy diagnosis and the relationship between impairments and function. Phys Ther 1991;71:499-504.
Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 2004;1(2): 273-83.
Stambler N, Charatan M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology 1998;50:66-72.
Damiano AM, Patrick DL, Guzman GI, Gawel MJ, Gelinas DF, Natter HM, et al. Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies. Med Care 1999;37(1): 15-26.
Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revised: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotr Lat Scler Other Motor Neuron Disord 2000;1(5):293-9.
Medical Research Council. Aids to the examination of the peripheral nervous system. Edinburgh: WB Saunders, 2000, 1-2.
Czaplinski A, Yen AA, Appel SH. Amyotrophic Lateral Sclerosis: early predictors of prolonged survival. J Neurol 2006; 253:1428-36.
Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology 2005;64:1215-21.
Del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-9.
Brooks BR. Clinical epidemiology of amyotrophic lateral sclerosis. Neurol Clin 1996:14:399-420.
Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-15.
Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-64.
Werneck LC, Bezerra R, Neto OS, Scola RH. A clinical epidemiological study of 251 cases of amyotrophic lateral sclerosis in the south of Brazil. Arq Neuropsiquiatr 2007;65(2A):189-95.
Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: prepare for the worst and hope for the best. JAMA 2007;298(2):207-16.
Pozza AM, Delamura MK, Ramirez C, Valério NI, Marino LHC, Lamari NM. Physiotherapeutic conduct in amyotrophic lateral sclerosis. São Paulo Med J 2006;124(6):350-4.
Miller RG, Anderson FA, Bradley WG, Brooks BR, Mitsumoto H, Munsat TL, et al. The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group. Neurology 2000;54(1):53-7.
Trifirò G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, et al. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004, Pharmacoepidemiol Drug Saf 2007;16(5):552-9.
Gordon T, Hegedus J, Tam SL. Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 2004;26(2):174-85.
Swash M, Schwartz MS. What do we really know about amyotrophic lateral sclerosis? J Neurol Sci 1992;113:4-16.
Vainstein G, Gordon C, Gadoth N. HTLV-1 Associated Motor Neuron Disease Mimicking “Man-in-the-Barrel” Syndrome. Journal of Clinical Neuromuscular Disease 2005;6(3):127-31.
Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003;61:1503-7.
Gooch CL, Shefner JM. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl 1):104-7.
Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 1999;53:1239-46.
Wagner-Sonntag E, Prosiegel M. Dysphagia. In: Ollver D, Borasio GD, Walsh D (eds.). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2 ed. Oxford: Oxford University Press, 2006, 95-109.
Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 1999;169:118-25.
Kubler A, Nijboer F, Mellinger J, 6 autores, et al. Patients with ALS can use sensoriomotor rhythms to operate a brain-computer interface. Neurology 2005;64:1775-7.
Belsh JM, Schiffman PL (eds.). Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk. New York: Futura, 1996, 41-3.
Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan /quinidine: a randomized trial. Neurology 2004;63:1364-70.
Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M. Home ventilator for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family and physician attitudes. Neurology 1993;43:438-43.
Desnuelle C, Bruno M, Soriani MH, Perrin C. Quelles sont les modalités de thérapie physique symptomatique incluant les techniques de désencombrement bronchique? Rev Neurol (Paris) 2006;162(2):4S244-52.
Português
English
Español
